Omnicell Balance Sheet Health
Financial Health criteria checks 5/6
Omnicell has a total shareholder equity of $1.2B and total debt of $340.7M, which brings its debt-to-equity ratio to 27.4%. Its total assets and total liabilities are $2.1B and $877.6M respectively. Omnicell's EBIT is $10.2M making its interest coverage ratio -0.4. It has cash and short-term investments of $369.2M.
Key information
27.4%
Debt to equity ratio
US$340.72m
Debt
| Interest coverage ratio | -0.4x |
| Cash | US$369.20m |
| Equity | US$1.24b |
| Total liabilities | US$877.65m |
| Total assets | US$2.12b |
Recent financial health updates
Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Oct 07
Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt
May 25Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?
Jan 15Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?
Aug 08Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Apr 11We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt
Jan 01Recent updates
Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Feb 14Omnicell Q4 Earnings: Ignore The Short-Term Noise
Feb 12Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 09Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 28Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues
Nov 27Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next
Nov 02Omnicell Q3 Earnings: Look At The Growth Segment
Nov 01Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Oct 31Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Oct 07Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%
Aug 02Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?
Jul 11Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price
Jun 16Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt
May 25An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued
Mar 28Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 29Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Feb 23Omnicell Is Building A Strong Moat
Feb 22Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?
Jan 15Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price
Dec 25Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?
Dec 06Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%
Nov 10Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?
Sep 06Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?
Aug 08Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching
Jul 02A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)
Jun 08Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital
Apr 29Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Apr 11At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?
Mar 23Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?
Feb 28Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)
Jan 15We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt
Jan 01Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?
Nov 17Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers
Nov 03Omnicell launches Specialty Pharmacy Services
Oct 11Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly
Sep 30Financial Position Analysis
Short Term Liabilities: OMCL's short term assets ($815.5M) exceed its short term liabilities ($595.7M).
Long Term Liabilities: OMCL's short term assets ($815.5M) exceed its long term liabilities ($282.0M).
Debt to Equity History and Analysis
Debt Level: OMCL has more cash than its total debt.
Reducing Debt: OMCL's debt to equity ratio has increased from 5.9% to 27.4% over the past 5 years.
Debt Coverage: OMCL's debt is well covered by operating cash flow (55.1%).
Interest Coverage: OMCL earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 04:10 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omnicell, Inc. is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| K. Juhng | BB&T Capital Markets |
| William Sutherland | Benchmark Company |
| Raymond Myers | Benchmark Company |